Health Condition 1: null- Patients with active rheumatoid arthritis
Conditions
Interventions
Intervention1: AB1010: patient will receive a total daily dose of 3 mg/kg/day of masitinib/placebo in addition to methotrexate/placebo. Patients will be treated for 24 weeks (with possible treatment e
Sponsors
AB SCIENCE
Maya Clinicals
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patient with rheumatoid arthritis diagnosed according to American College of Rheumatology (ACR) criteria for at least 6 months. 2. Patient with ACR functional class I-III. 3. Patient who have active RA. 4. Patient who failed (defined as active RA with stable dose during 3 months) methotrexate at a dose >= 15 mg/week or any DMARD including biologics drugs if patients previously failed methotrexate at a dose >= 15 mg/week or methotrexate at a dose >= 15 mg/week in combination with any DMARD including biologics drugs (Biologic drugs being defined as any of the following therapies: anti-TNFα, Anti-CD20, Anti-IL1, Anti-IL6, CTLA4). 5. Patient with a disease onset at > 16 years of age.
Exclusion criteria
Exclusion criteria: A patient must not be enrolled if he/she fulfills one of the following exclusion criteria: 1. Patient from whom the use of methotrexate is contraindicated as per its SPC (i.e. patient with severe renal or liver failure, patient with pre-existing blood dyscrasia, patient with alcohol abuse, patient with acute or chronic infection, patient with methotrexate intolerance, patient being treated with live attenuated vaccine) 2. Patient with documented fibromyalgia 3. Patient who have had a major surgery within 2 weeks prior to study entry 4. Patient with lactose intolerance 5. Patient presenting with cardiac disorders defined by at least one of the following conditions: • Patient with recent cardiac history (within 6 months) of: - Acute coronary syndrome - Acute heart failure (class III or IV of the NYHA classification) - Significant ventricular arrhythmia (persistent ventricular tachycardia, ventricular fibrillation, resuscitated sudden death) • Patient with cardiac failure class III or IV of the NYHA classification • Patient with severe conduction disorders which are not prevented by permanent pacing (atrio-ventricular block 2 and 3, sino-atrial block) • Syncope without known aetiology within 3 months • Uncontrolled severe hypertension, according to judgment of the investigator, or symptomatic hypertension 6. Patient with history of primary malignancy 7. Patient with a severe and/or uncontrolled medical condition 8. Pregnant or lactating woman 9. Patient with history of poor compliance or history of drug/alcohol abuse, or excessive alcohol beverage consumption that would interfere with the ability to comply with the study protocol, or current or past psychiatric disease that might interfere with the ability to comply with the study protocol or give informed consent. 10. Patient who were treated with methotrexate >20 mg cannot be included in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cumulative response on ACR20 (ie. response from week 8 to week 24).Timepoint: Cumulative response on ACR20 (ie. response from week 8 to week 24). | — |
Secondary
| Measure | Time frame |
|---|---|
| Cumulative response on ACR50 (ie. response from week 8 to week 24), Cumulative response on ACR70 (ie. response from week 8 to week 24), Cumulative response on ACR90 (ie. response from week 8 to week 24)Timepoint: Cumulative response on ACR50, 70, 90 (ie. response from week 8 to week 24). | — |
Countries
Czech Republic, France, Germany, Greece, India, Poland, Romania, Slovakia, Spain, Thailand, United States of America
Contacts
Public ContactJhansi Reddy
Maya Clinicals Drug Development Pvt Ltd.
Outcome results
None listed